Topics

Old and new breakthroughs in neuromyelitis optica.

08:00 EDT 1st April 2020 | BioPortfolio

Summary of "Old and new breakthroughs in neuromyelitis optica."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: The Lancet. Neurology
ISSN: 1474-4465
Pages: 280-281

Links

DeepDyve research library

PubMed Articles [158 Associated PubMed Articles listed on BioPortfolio]

Neuromyelitis optica and neuromyelitis optica spectrum disorders.

The review is devoted to up-to-date data on epidemiology, aspects of the pathogenesis of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD). The authors consider a role of ...

GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica.

We previously reported the association between blood-brain barrier (BBB) dysfunction and glucose-regulated protein 78 (GRP 78) autoantibodies in neuromyelitis optica (NMO).

Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare.

Inflammatory demyelinating disease of the central nervous system characterized by aseptic meningitis is rare and can be easily confused with intracranial infection. Here, we investigated the clinical ...

Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder ?

The symptoms of multiple sclerosis (MS) can overlap with neuromyelitis optica spectrum disorder (NMOSD). Although testing is available for aquaporin 4 (AQP4) and myelin oligodendrocyte glycoprotein (M...

Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.

Neuromyelitis optica spectrum disorder (NMOSD) most commonly, although not exclusively, targets optic nerves and spinal cord. Untreated, early and severe disability is common. We evaluated the long-te...

Clinical Trials [59 Associated Clinical Trials listed on BioPortfolio]

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.

A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.

Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic ne...

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMO...

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.

Medical and Biotech [MESH] Definitions

A syndrome characterized by acute OPTIC NEURITIS in combination with acute MYELITIS, TRANSVERSE. Demyelinating and/or necrotizing lesions form in one or both optic nerves and in the spinal cord. The onset of optic neuritis and myelitis may be simultaneous or separated by several months. (J Neurol Neurosurg Psychiatry 1996 Apr;60(4):382-387)

Quick Search


DeepDyve research library

Searches Linking to this Article